Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | October 01, 2026 | October 02, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 07, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | December 07, 2023 | December 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,995 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 5,000 · Balance 15,995 Row 2 · 2026-10-01 · Sale · Disposed 5,000 · Balance 10,995 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.03 · Expires 2027-02-23 | Direct | 10,000 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 5,000 · Balance 10,000 F3: The stock option is fully vested and exercisable. F4: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock option is fully vested and exercisable.
F4: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date December 07, 2023 · Filed December 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.55 · Expires 2033-12-06 | Direct | 37,000 |
Reported balance
After 2023-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-07 · Grant · Acquired 37,000 · Balance 37,000 F1: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of December 7, 2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CEPHEID
Report date November 04, 2016 · Filed November 07, 2016
Section 16 reporting ended · disclosed 2016-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-11-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-31 · Gift · Disposed 3,350 · Balance 11,567 Row 2 · 2016-11-04 · Disposition to issuer · Disposed 11,567 · Balance 0 F1: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest. F2: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration"). |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.72 · Expires 2019-04-24 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-04 · Disposition to issuer · Disposed 7,800 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.13 · Expires 2020-04-30 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-04 · Disposition to issuer · Disposed 7,800 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.59 · Expires 2021-04-22 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.70 · Expires 2022-04-28 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F5: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.59 · Expires 2023-04-26 | Direct | 0 |
Reported balance
After 2016-11-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-04 · Disposition to issuer · Disposed 16,300 · Balance 0 F6: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price. F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This number includes RSUs previously reported on Table I that at closing, were accelerated and converted into the right to receive $53 per share, without interest.
F2: On September 2, 2016, the Issuer entered into an Agreement and Plan of Merger ("Merger Agreement") with Danaher Corporation, a Delaware corporation (the "Acquirer"), and Copper Merger Sub, Inc., a California corporation and a wholly-owned subsidiary of the Acquirer. Upon the closing of the transactions contemplated by the Merger Agreement on November 4, 2016 (the "Closing"), each of the Reporting Person's shares of the Issuer's Common Stock was cancelled and converted into the right to receive $53.00, without interest (the "Merger Consideration").
F3: Upon the Closing, 100% of these options were cancelled and converted into the right to receive an amount of cash equal to the number of shares outstanding under this option multiplied by $53 minus the option exercise price.
F4: 100% of the shares subject to the grant vested and became exercisable on the one-year anniversary of the grant date.
F5: Upon the Closing, this option was cancelled and ceased to exist without receiving any payment therefor.
F6: Upon the Closing, 100% of this option's vesting was accelerated and converted into the right to receive an amount of cash equal to the number of shares outstanding under the option multiplied by $53.00 minus the exercise price.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectThe Renton Family Community Property Trust | 0 |
Reported balance
After 2020-07-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 2,826 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-02 · Disposition to issuer · Disposed 59,092 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F4: In connection with the Merger, these options were accelerated and canceled without payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:47 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock · Derivative | 5,000 | $0.00 Strike: $18.03 | $0.00 |
DisclosureSEC source: 0001187333-26-000004 · form4-10022026_091051.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · balance_after: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:47 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 5,000 | $49.87 | $249,371.50 |
DisclosureSEC source: 0001187333-26-000004 · form4-10022026_091051.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,995 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:47 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,000 | $18.03 | $90,150.00 |
DisclosureSEC source: 0001187333-26-000004 · form4-10022026_091051.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001187333-26-000003 · form4-06172026_040606.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001187333-26-000003 · form4-06172026_040606.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $32.17 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 20 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 19 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $10.87 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 18 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 17 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 16 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 15 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $17.02 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 14 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 13 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 12 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 11 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 10 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 9 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 8 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-02-11 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $16.56 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 7 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-02-11 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $50.47 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 6 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-07 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $68.88 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 5 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-07 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $76.79 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $104.81 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.03 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001187333-26-000002 · form4-04222026_100427.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001187333-26-000001 · form4-01082026_090157.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001187333-26-000001 · form4-01082026_090157.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:02 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock · Derivative | 10,231 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001415889-25-021486 · form4-08122025_080842.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,231 shares Expires 2025-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option grant was issued on August 14, 2015, is fully vested and exercisable until its expiration date of August 13, 2025. F5 · balance_after: In addition to the remaining options to purchase 10,231 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 101,820 shares of common stock, which options vest according to their terms. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:02 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 7,121 | $19.70 | $140,255.22 |
DisclosureSEC source: 0001415889-25-021486 · form4-08122025_080842.xml · nonDerivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,965 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of August 13, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.48 to $20.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:02 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,110 | $19.44 | $60,458.40 |
DisclosureSEC source: 0001415889-25-021486 · form4-08122025_080842.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,086 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of August 13, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.375 to $19.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:02 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,231 | $6.93 | $70,900.83 |
DisclosureSEC source: 0001415889-25-021486 · form4-08122025_080842.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 17:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock · Derivative | 20,925 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001415889-25-019242 · form4-07032025_050730.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,925 shares Expires 2025-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025. F5 · balance_after: In addition to the remaining options to purchase 20,925 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 112,051 shares of common stock, which options vest according to their terms. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 17:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 13,675 | $23.82 | $325,782.26 |
DisclosureSEC source: 0001415889-25-019242 · form4-07032025_050730.xml · nonDerivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,965 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of July 5, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.56 to $24.015 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 17:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 7,250 | $23.09 | $167,408.30 |
DisclosureSEC source: 0001415889-25-019242 · form4-07032025_050730.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,640 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of July 5, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.425 to $23.395 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 17:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 20,925 | $6.93 | $145,010.25 |
DisclosureSEC source: 0001415889-25-019242 · form4-07032025_050730.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,015 | $23.97 | $72,269.55 |
DisclosureSEC source: 0001415889-25-017819 · form4-06202025_080641.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,965 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. F2 · shares: Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017588 · form4-06172025_100644.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017588 · form4-06172025_100644.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:29 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001037 · form4-01072025_100100.xml · derivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:29 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001037 · form4-01072025_100100.xml · derivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:35 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock · Derivative | 10,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001415889-24-028094 · form4-12032024_091237.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,925 Underlying: Common Stock · 10,000 shares Expires 2025-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025. F3 · balance_after: In addition to the remaining options to purchase 20,925 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 95,541 shares of common stock, which options vest according to their terms. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:35 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001415889-24-028094 · form4-12032024_091237.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,950 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options before their expiration. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:35 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $6.93 | $69,300.00 |
DisclosureSEC source: 0001415889-24-028094 · form4-12032024_091237.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:45 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock · Derivative | 10,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001415889-24-019676 · form4-07172024_080731.xml · derivative · entry 4 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,925 Underlying: Common Stock · 10,000 shares Expires 2025-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:45 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,897 | $30.98 | $89,753.98 |
DisclosureSEC source: 0001415889-24-019676 · form4-07172024_080731.xml · nonDerivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,950 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options before their expiration. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:45 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 7,103 | $30.50 | $216,668.49 |
DisclosureSEC source: 0001415889-24-019676 · form4-07172024_080731.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,847 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options before their expiration. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:45 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $6.93 | $69,300.00 |
DisclosureSEC source: 0001415889-24-019676 · form4-07172024_080731.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2024 Filed Jun 19, 2024 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,950 | $23.16 | $45,162.00 |
DisclosureSEC source: 0001415889-24-017507 · form4-06192024_120659.xml · nonDerivative · entry 2 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024 Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017507 · form4-06192024_120659.xml · derivative · entry 3 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017507 · form4-06192024_120659.xml · nonDerivative · entry 1 RENTON HOLLINGS · CIK 0001187333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.